COMMUNIQUÉS West-GlobeNewswire

BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles
11/04/2024
PRESS RELEASE - PRIVILEGED INFORMATION A final circular of the creditors on the basis of XX 83/23 of the Economic Law Code (ELC) will take place before the Court grants authorisation, in accordance with article XX 83/26 [...]
BioSenic et son praticien de la restructuration (Me Yves Brulard) soumettent un plan de restructuration global engageant les années 2024-2030 au Tribunal de l’entreprise de Nivelles
11/04/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Une circularisation finale des créanciers sur base de XX 83/23 du Code de Droit Economique (CDE) va intervenir avant que le Tribunal n’autorise, conformément à l'article XX [...]
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
11/04/2024
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44 [...]
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
11/04/2024
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
11/04/2024
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies fera une présentation à la 2024 Bloom Burton & Co. Healthcare Investor Conference
11/04/2024
MONTRÉAL, 11 avr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation [...]
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
11/04/2024
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
RadNet Announces Pricing and Upsizing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction
11/04/2024
LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has [...]
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
11/04/2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]
Novartis tender offer for MorphoSys AG commences
11/04/2024
Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG (“MorphoSys”), [...]
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
11/04/2024
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer Data presented at AACR 2024 shows MACO-355 is highly potent in [...]
Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024
11/04/2024
ORION CORPORATION PRESS RELEASE 11 APRIL 2024 at 9.30 EEST Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024 Orion will publish Interim Report for January–March 2024 on Thursday [...]
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
11/04/2024
EINDHOVEN, the Netherlands, April 11, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, [...]
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
11/04/2024
The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and Company Once approved, the test will aid healthcare providers in identifying amyloid [...]
Record revenue of €209 million in first quarter reflecting 15% topline growth
11/04/2024
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading [...]
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
11/04/2024
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its [...]
Idorsia takes steps to address short-term liquidity needs
11/04/2024
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of Idorsia Main [...]
CARBIOS announces fiscal-year 2023 financial results and confirms 2024 calendar for industrial and commercial roll-out
11/04/2024
CARBIOS Group’s solid financial structure: cash position of €192 million on December 31, 2023 Construction progress of world’s first PET 1 biorecycling plant in France: in line with delivery targets for customers in [...]
CARBIOS présente ses résultats annuels 2023 et confirme le calendrier 2024 de son déploiement industriel et commercial
11/04/2024
Solide structure financière du Groupe CARBIOS : position de trésorerie de 192 millions d’euros au 31 décembre 2023 Avancée de la construction, en France, de la première usine au monde de biorecyclage du PET 1 : [...]

Pages